The short version of circadian rhythm fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-13. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Solvent extraction is used extensively in separation and purification processes. In its simplest form a reaction is performed in an organic solvent and unwanted by-products are removed by extraction into water at a particular pH. A metal ion may be extracted from an aqueous phase into an organic phase in which the salt is not soluble, by adding a ligand. The ligand, La−, forms a complex with the metal ion, Mb+, [MLx](b−ax)+ which has a strongly hydrophobic outer surface. If the complex has no electrical charge it will be extracted relatively easily into the organic phase. If the complex is charged, it is extracted as an ion pair. The additional ligand is not always required. For example, uranyl nitrate, UO2(NO3)2, is soluble in diethyl ether because the solvent itself acts as a ligand. This property was used in the past for separating uranium from other metals whose salts are not soluble in ether. Currently extraction into kerosene is preferred, using a ligand such as tri-n-butyl phosphate, TBP. In the PUREX process, which is commonly used in nuclear reprocessing, uranium(VI) is extracted from strong nitric acid as the electrically neutral complex [UO2(TBP)2(NO3)2]. The strong nitric acid provides a high concentration of nitrate ions which pushes the equilibrium in favour of the weak nitrato complex. Uranium is recovered by back-extraction (stripping) into weak nitric acid. Plutonium(IV) forms a similar complex, [PuO2(TBP)2(NO3)2] and the plutonium in this complex can be reduced to separate it from uranium.
Vegans had a lower dietary intake of vitamin D and lower serum 25(OH)D when compared to omnivores, with lacto-ovo-vegetarians falling in between due to the vitamin content of egg yolks and fortified dairy products. Governments have mandated or voluntary food fortification programs to bridge the difference in, respectively, 15 and 10 countries. The US is one of the few mandated countries. The original fortification practices, circa the early 1930s, were limited to cow's milk, which had a large effect on reducing infant and child rickets. In July 2016 the US Food and Drug Administration approved the addition of vitamin D to plant milk beverages intended as milk alternatives, such as beverages made from soy, almond, coconut, and oats. At an individual level, people may choose to consume a multivitamin/mineral product or else a vitamin-D-only product. There are many disease states, medical treatments, and medications that put people at risk for vitamin D deficiency. Chronic diseases that increase risk include kidney and liver failure, Crohn's disease, inflammatory bowel disease, and malabsorption syndromes such as cystic fibrosis, and hyper- or hypo-parathyroidism. Obesity sequesters vitamin D in fat tissues, thereby lowering serum levels, but bariatric surgery to treat obesity interferes with dietary vitamin D absorption, also causing deficiency. Medications interacting with vitamin D metabolism include antiretrovirals, anti-seizure drugs, glucocorticoids, systemic antifungals such as ketoconazole, cholestyramine, and rifampicin.
The news media focused on Nixon's militaristic tone, describing his announcement with variations of the phrase "war on drugs". The day after Nixon's press conference, the Chicago Tribune proclaimed, "Nixon Declares War on Narcotics Use in US". In England, The Guardian headlined, "Nixon declares war on drug addicts." The US anti-drug campaign came to be commonly referred to as the war on drugs; the term also became used to refer to any government's prosecution of a US-style prohibition-based drug policy. Facing reelection, with drug control as a campaign centerpiece, Nixon formed the Office of Drug Abuse Law Enforcement (ODALE) in late 1971. ODALE, armed with new federal enforcement powers, began orchestrating drug raids nationwide to improve the administration's watchdog reputation. In a private conversation while helicoptering over Brooklyn, Nixon was reported to have commented, "You and I care about treatment. But those people down there, they want those criminals off the streets." From 1972 to 1973, ODALE performed 6,000 drug arrests in 18 months, the majority of the arrested black. In 1972, the Shafer Commission released its report, "Marihuana: A Signal of Misunderstanding", comprising a review of the medical literature and a national drug survey. It recommended decriminalization for personal possession and use of small amounts of cannabis, and prohibition only of supply. The conclusion was not acted on by Nixon or by Congress.
Sources: en.wikipedia.org
== Income, wealth and income distribution == Average per capita income is high in an international context. According to the World Bank, gross national income per capita was the tenth-highest in the world at $55,220 in 2017. Correcting for purchasing power, income was Int$52,390 or 16th-highest among the 187 countries. During the last three decades household saving rates in Denmark have increased considerably. This is to a large extent caused by two major institutional changes: A series of tax reforms from 1987 to 2009 considerably reduced the effective subsidization of private debt implicit in the rules for tax deductions of household interest payments. Secondly, compulsory funded pension schemes became normal for most employees from the 1990s. Over the years, the wealth of the Danish pension funds have accumulated so that in 2016 it constituted twice the size of Denmark's GDP. The pension wealth consequently is a very important both for the life-cycle of a typical individual Danish household and for the national economy. A large part of the pension wealth is invested abroad, thus giving rise to a fair amount of foreign capital income. In 2015, average household assets were more than 600% of their disposable income, among OECD countries second only to the Netherlands. At the same time, average household gross debt was almost 300% of disposable income, which is also at the highest level in OECD. Household balance sheets are consequently very large in Denmark compared to most other countries.
==== Monosaccharide reduction ==== There are many ways silver nanoparticles can be synthesized; one method is through monosaccharides. This includes glucose, fructose, maltose, maltodextrin, etc., but not sucrose. It is also a simple method to reduce silver ions back to silver nanoparticles as it usually involves a one-step process. There have been methods that indicated that these reducing sugars are essential to the formation of silver nanoparticles. Many studies indicated that this method of green synthesis, specifically using Cacumen platycladi extract, enabled the reduction of silver. Additionally, the size of the nanoparticle could be controlled depending on the concentration of the extract. The studies indicate that the higher concentrations correlated to an increased number of nanoparticles. Smaller nanoparticles were formed at high pH levels due to the concentration of the monosaccharides. Another method of silver nanoparticle synthesis includes the use of reducing sugars with alkali starch and silver nitrate. The reducing sugars have free aldehyde and ketone groups, which enable them to be oxidized into gluconate. The monosaccharide must have a free ketone group because in order to act as a reducing agent it first undergoes tautomerization. In addition, if the aldehydes are bound, it will be stuck in cyclic form and cannot act as a reducing agent. For example, glucose has an aldehyde functional group that is able to reduce silver cations to silver atoms and is then oxidized to gluconic acid. The reaction for the sugars to be oxidized occurs in aqueous solutions.
Only two of the Russian frigates provided important services in the Caribbean in defense of the island of Cuba, although they only made the one-way trip, they got lost, sunk when they arrived in Havana.
Furthermore, the nitrogen atom may be replaced by a phosphorus, arsenic, or antimony atom (the heavier nonmetallic pnictogens), creating a phosphonium (PH+4) or arsonium (AsH+4) cation that can itself be substituted similarly; while stibonium (SbH+4) itself is not known, some of its organic derivatives are characterised.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.